NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
ORBACTIV (oritavancin) by CorMedix is cytochrome p450 2c19 inhibitors [moa]. First approved in 2014.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORBACTIV (oritavancin) is a lipoglycopeptide antibiotic administered intravenously as a powder for injection. It is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms. The drug works as a cytochrome P450 2C19 inhibitor with bactericidal activity against resistant pathogens.
$0.231MPart D
Peak8.9 years to LOEProduct is at peak lifecycle stage with minimal Medicare Part D penetration (69 claims in 2023), indicating a mature but niche positioning with limited commercial team expansion expected.
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Lipoglycopeptide Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ORBACTIV offers limited high-visibility career growth given low Medicare utilization (69 claims annually) and peak-to-LOE lifecycle positioning. Roles focus on defending market share, optimizing reimbursement, and executing niche ABSSSI positioning rather than launch excitement or pipeline innovation.
Brand ManagerMedical Science Liaison
Worked on ORBACTIV at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.